Merck's preventive treatment for respiratory syncytial virus cleared a regulatory hurdle, with a European Medicines Agency committee recommending an expanded indication.
The Committee for Medicinal Products for Human Use adopted a positive opinion recommending the use of the treatment, called Enflonsia, to prevent respiratory syncytial virus, or RSV, a lower respiratory tract disease in certain children up to 24 months of age who remain at increased risk for severe disease through their second RSV season, Merck said Friday.
The recommendation will now be reviewed by the European Commission for marketing authorization in the European Union, Iceland, Liechtenstein and Norway. A final decision is expected within the next two months, according to Merck.
"For some children, the risk of severe RSV does not end after their first RSV season and they remain at increased risk for serious cases of RSV-related bronchiolitis or pneumonia that can require hospitalization," said Macaya Douoguih, therapeutic area head of global clinical development at Merck Research Laboratories.
The positive opinion is an important step toward bringing Enflonsia to children in the region who remain at increased risk, Douoguih said.
Comments